NASDAQ:AGRX Agile Therapeutics (AGRX) Stock Forecast, Price & News $1.80 +0.04 (+2.27%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$1.76▼$1.9350-Day Range$1.73▼$3.1252-Week Range$1.65▼$16.00Volume29,032 shsAverage Volume57,997 shsMarket Capitalization$3.47 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Agile Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside372.2% Upside$8.50 Price TargetShort InterestHealthy0.58% of Float Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment1.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.05) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.41 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAgile Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Agile Therapeutics has a forecasted upside of 372.2% from its current price of $1.80.Amount of Analyst CoverageAgile Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.58% of the float of Agile Therapeutics has been sold short.Short Interest Ratio / Days to CoverAgile Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Agile Therapeutics has recently decreased by 48.31%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAgile Therapeutics does not currently pay a dividend.Dividend GrowthAgile Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgile Therapeutics has received a 56.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Estradiol medication" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agile Therapeutics is -1.59. Previous Next 3.3 News and Social Media Coverage News SentimentAgile Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Agile Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for AGRX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows3 people have added Agile Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agile Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.50% of the stock of Agile Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 7.52% of the stock of Agile Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agile Therapeutics are expected to grow in the coming year, from ($6.05) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agile Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agile Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Agile Therapeutics (NASDAQ:AGRX) StockAgile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.Read More AGRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGRX Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comMaxim Group Upgrades Agile Therapeutics (NASDAQ:AGRX) to BuySeptember 5, 2023 | finance.yahoo.comAgile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 25, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.August 17, 2023 | msn.comAgile ($AGRX) Says It's On Track To Hit $25-$30M Net Annual Revenue After A Strong Performance In Q2August 11, 2023 | finance.yahoo.comAgile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 9, 2023 | finance.yahoo.comAgile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 26, 2023 | finance.yahoo.comAgile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023September 25, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.July 19, 2023 | finance.yahoo.comThis Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With AfaxysJuly 18, 2023 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of WomenJuly 18, 2023 | msn.comNASDAQ: $AGRX Biden's Executive Order Boosts Adoption Of Agile Therapeutics' Contraceptive PatchJuly 14, 2023 | benzinga.comAgile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of WomenJuly 11, 2023 | finance.yahoo.comAgile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive CoverageJuly 6, 2023 | fool.comAgile Therapeutics (NASDAQ: AGRX)June 30, 2023 | finance.yahoo.comAgile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?June 29, 2023 | benzinga.comH.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control PatchJune 28, 2023 | finance.yahoo.comThe Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of CareJune 27, 2023 | finance.yahoo.comPresident Biden’s new executive order could help American women get better birth controlJune 26, 2023 | benzinga.comThis Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023June 26, 2023 | finance.yahoo.comAgile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse MembersJune 23, 2023 | finance.yahoo.comAgile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning ServicesJune 15, 2023 | finance.yahoo.comAgile Therapeutics Announces the Availability of Twirla® through FPA Women’s HealthJune 14, 2023 | msn.comAgile Therapeutics Rises on Teaming up with vitaCare for Expanding Twirla’s ReachJune 14, 2023 | finance.yahoo.comWhy Agile Therapeutics Stock Is Trading Higher TodayJune 13, 2023 | finance.yahoo.comAgile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®June 8, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Agile Therapeutics (AGRX), Check-Cap (CHEK) and Doximity (DOCS)See More Headlines Receive AGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGRX Company Calendar Last Earnings8/09/2023Today9/25/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGRX CUSIPN/A CIK1261249 Webwww.agiletherapeutics.com Phone(609) 683-1880FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.50 High Stock Price Forecast$12.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+369.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($39.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,410,000.00 Net Margins-201.02% Pretax Margin-116.82% Return on Equity-2,658.43% Return on Assets-192.51% Debt Debt-to-Equity RatioN/A Current Ratio0.76 Quick Ratio0.60 Sales & Book Value Annual Sales$10.88 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value($6.83) per share Price / Book-0.27Miscellaneous Outstanding Shares1,930,000Free Float1,916,000Market Cap$3.50 million OptionableOptionable Beta1.13 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Alfred F. Altomari (Age 64)Chairman, Pres & CEO Comp: $644.4kMr. Geoffrey P. Gilmore (Age 57)Sr. VP & Chief Admin. Officer Comp: $478.92kDr. Paul Korner M.B.A. (Age 57)M.D., Sr. VP & Chief Medical Officer Comp: $480.4kMr. Scott M. Coiante (Age 56)CFO, Sr. VP & Treasurer Matthew RileyHead of Investor Relations & Corp. CommunicationsMr. Robert G. Conway M.E. (Age 65)Sr. VP and Chief Corp. Planning & Supply Chain Officer Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D. (Age 55)M.P.H., Consultant Ms. Amy Welsh (Age 52)Sr. VP & Chief Commercial Officer Joseph D'UrsoControllerMore ExecutivesKey CompetitorsBellicum PharmaceuticalsNASDAQ:BLCMEvoke PharmaNASDAQ:EVOKDermata TherapeuticsNASDAQ:DRMAAditxtNASDAQ:ADTXAridis PharmaceuticalsNASDAQ:ARDSView All CompetitorsInstitutional OwnershipState Street CorpBought 10,843 shares on 8/14/2023Ownership: 1.095%View All Institutional Transactions AGRX Stock - Frequently Asked Questions Should I buy or sell Agile Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGRX shares. View AGRX analyst ratings or view top-rated stocks. What is Agile Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued 12-month target prices for Agile Therapeutics' shares. Their AGRX share price forecasts range from $5.00 to $12.00. On average, they anticipate the company's share price to reach $8.50 in the next year. This suggests a possible upside of 369.0% from the stock's current price. View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts. How have AGRX shares performed in 2023? Agile Therapeutics' stock was trading at $0.2270 at the start of the year. Since then, AGRX stock has increased by 698.3% and is now trading at $1.8122. View the best growth stocks for 2023 here. Are investors shorting Agile Therapeutics? Agile Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 10,700 shares, a decrease of 48.3% from the August 15th total of 20,700 shares. Based on an average trading volume of 119,400 shares, the short-interest ratio is currently 0.1 days. Approximately 0.6% of the shares of the stock are short sold. View Agile Therapeutics' Short Interest. When is Agile Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our AGRX earnings forecast. How were Agile Therapeutics' earnings last quarter? Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its quarterly earnings results on Wednesday, August, 9th. The specialty pharmaceutical company reported ($3.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.48) by $0.38. The specialty pharmaceutical company earned $5.50 million during the quarter, compared to analysts' expectations of $4.68 million. Agile Therapeutics had a negative trailing twelve-month return on equity of 2,658.43% and a negative net margin of 201.02%. When did Agile Therapeutics' stock split? Agile Therapeutics's stock reverse split on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What guidance has Agile Therapeutics issued on next quarter's earnings? Agile Therapeutics issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $25.00 million-$30.00 million, compared to the consensus revenue estimate of $21.66 million. What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX). What is Agile Therapeutics' stock symbol? Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX." Who are Agile Therapeutics' major shareholders? Agile Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (1.10%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Agile Therapeutics? Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Agile Therapeutics' stock price today? One share of AGRX stock can currently be purchased for approximately $1.81. How much money does Agile Therapeutics make? Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $3.50 million and generates $10.88 million in revenue each year. The specialty pharmaceutical company earns $-25,410,000.00 in net income (profit) each year or ($39.56) on an earnings per share basis. How can I contact Agile Therapeutics? Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com. This page (NASDAQ:AGRX) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agile Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.